-
SC 79: A Practical Akt Activator Workflow
2026-09-21
SC 79 is a cytosolic Akt activator for dissecting survival signaling without changing total Akt abundance. This workflow connects neuronal protection, ischemia models, and inflammation-focused pathway studies with practical dosing, washout, assay, and troubleshooting guidance.
-
GSK126: Practical EZH2 Inhibitor Workflows
2026-09-20
GSK126 provides a high-affinity pharmacological route to test how EZH2/PRC2 activity controls H3K27me3, gene silencing, and tumor-cell behavior. This guide translates the compound into reproducible workflows for cancer epigenetics research while clarifying how findings from an antiviral lncRNA study can inform, but not replace, oncology assay design.
-
Protein Integrity in EGFR Resistance
2026-09-19
Hypoxia-driven EGFR inhibitor resistance illustrates why protein preservation is a translational variable. This article connects FGFR1–MAPK biology with practical extraction strategy and explains when an EDTA-free Protease Inhibitor Cocktail can protect phosphorylation-sensitive and interaction-based assays.
-
Brefeldin A: Reliable Assay Design
2026-09-18
Learn how Brefeldin A, SKU B1400, can be integrated into viability, cytotoxicity, trafficking, and apoptosis workflows without confusing transport effects with cell death. This scenario-based guide connects dose selection, solvent handling, endpoint interpretation, and vendor evaluation to practical laboratory decisions.
-
Mycobacterium tuberculosis WecA: Kinetics and Purification
2026-09-18
The reference study establishes a practical route for producing and analyzing Mycobacterium tuberculosis WecA, a difficult 11-transmembrane-domain enzyme involved in mycobacterial cell-wall assembly. By combining tunable expression in Escherichia coli Lemo21(DE3), affinity purification, mass-spectrometric identification, and UMP-based activity detection, the authors created a foundation for kinetic analysis and WecA inhibitor discovery.
-
A1 vs AMD3100 in Colorectal Cancer Models
2026-09-17
Khorramdelazad and colleagues evaluated the fluorinated CXCR4 inhibitor A1 against AMD3100 across molecular, cellular, and mouse colorectal cancer models. A1 showed stronger predicted receptor binding, suppressed CT-26 cell proliferation and migration, reduced immunosuppressive tumor-microenvironment signals, and produced better tumor-control outcomes than AMD3100 in the reported preclinical experiments.
-
MDL 28170: A Selective Calpain Inhibitor Workflow
2026-09-17
MDL 28170 combines cell permeability, brain access, and nanomolar inhibition of calpain and cathepsin B for mechanistic neuroprotection research. This workflow translates recent BDNF/TrkB findings into practical assay design while addressing formulation, target attribution, and cross-model validation.
-
Carvedilol Workflows for Receptor Research
2026-09-16
A practical guide to using Carvedilol in β-adrenergic receptor research, oxidative stress inhibition, vascular remodeling, and hematopoietic regeneration studies. The workflow emphasizes receptor-selectivity controls, solvent management, and the distinct risks of nonselective blockade after allogeneic transplantation.
-
MLKL Polymerization and Lysosomal Permeabilization
2026-09-16
This study identifies lysosomal membrane permeabilization as a key execution step in MLKL-driven necroptosis. By combining live-cell imaging with MLKL and cathepsin B perturbation, the authors show that MLKL polymers disrupt lysosomes, release cathepsin B, and accelerate cell death before plasma membrane rupture.
-
SIRT3-SUMO, Treg Differentiation, and Asthma
2026-09-15
The reference study identifies an SIRT3–SUMO–fatty acid oxidation axis that links cellular metabolism to N-glycosylation and regulatory T-cell differentiation in asthma. Its combination of transcriptomic analysis, an OVA-sensitized model, ex vivo T-cell differentiation, and molecular perturbation provides a mechanistic framework for understanding how Treg abundance may influence both Th2 and non-Th2 airway inflammation.
-
ZK53 Activates ClpP to Arrest Lung Cancer Growth
2026-09-15
The reference study identifies ZK53 as a selective activator of human mitochondrial ClpP and shows that it suppresses lung squamous cell carcinoma through mitochondrial proteostasis failure, impaired oxidative phosphorylation, and ATM-linked DNA damage signaling. Its combination of structural, cellular, mechanistic, and animal-model evidence provides a framework for studying cell cycle arrest induction through mitochondrial stress.
-
Coumestrol, Ferroptosis, and RA-FLS Mechanisms
2026-09-14
A 2026 study identifies a TRIM3–PMAIP1 regulatory axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. Its layered cellular, inflammatory, mitochondrial, and gene-regulatory assays provide a mechanistic framework for studying how synoviocyte death may limit pathological proliferation and cytokine production.
-
AI-10-49: A RUNX1-Restoring AML Research Tool
2026-09-14
AI-10-49 is a selective CBFβ-SMMHC inhibitor for dissecting inv(16) acute myeloid leukemia biology. This article presents a causal assay framework that connects fusion-protein disruption with RUNX1 reactivation, N-MYC/eIF4G1 signaling, and leukemia phenotypes.
-
PTGER4–HDAC Signaling in Rectal Epithelium
2026-09-13
Anbazhagan et al. connect stromal-cell PGE2 production with PTGER4-dependent changes in class IIa HDAC phosphorylation and SPINK4 expression in rectal epithelial organoids. The study provides a mechanistic framework for interpreting epithelial repair signals while highlighting the need to preserve phosphorylation states during protein-based validation.
-
GRA12 and Cross-Strain Toxoplasma Virulence
2026-09-12
The reference study uses pooled in vivo CRISPR–Cas9 screening to identify virulence factors that remain important across diverse Toxoplasma gondii strains and mouse backgrounds. GRA12 emerged as a central dense-granule effector whose loss destabilized the parasitophorous vacuole, increased host-cell necrosis, and revealed a conserved mechanism shared with related coccidian parasites.